Date: 2017-02-15
Type of information: Private placement
Company: Fate Therapeutics (USA - CA)
Investors:
Amount: $42.9 million
Funding type: private placement
Planned used:
- Fate Therapeutics intends to use the net proceeds from the offering for clinical development and research activities, working capital and other general corporate purposes.
Others:
- • On December 15, 2017, Fate Therapeutics announced the closing of an underwritten public offering of 10,953,750 shares of its common stock, which included 1,428,750 shares that were issued pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $4.20 per share. Net proceeds from this offering were approximately $42.9 million, after deducting underwriting discounts and commissions and estimated offering expenses.
- • On December 13, 2017, Fate Therapeutics announced the pricing of an underwritten public offering of 9,525,000 shares of its common stock at a public offering price of $4.20 per share, before underwriting discounts, for an aggregate offering of $40.0 million. Fate Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,428,750 shares of its common stock. The proceeds to Fate Therapeutics from this offering are expected to be approximately $37.3 million after deducting underwriting discounts and commissions and other estimated offering expenses but excluding any exercise of the underwriters' option. All shares of common stock to be sold in the offering are being offered by Fate Therapeutics. The offering is expected to close on or about December 15, 2017, subject to customary closing conditions.
- • On December 12, 2017,Fate Therapeutics announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Fate Therapeutics. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
- Leerink Partners LLC and Piper Jaffray & Co. are acting as joint book-running managers for the offering.
Therapeutic area: Cancer - Oncology - Immunological diseases
Is general: Yes
